Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mithramycin Is a Gene-Selective Sp1 Inhibitor That Identifies a Biological Intersection between Cancer and Neurodegeneration

4 May 2011

Abstract excerpt

Oncogenic transformation of postmitotic neurons triggers cell death, but the identity of genes critical for degeneration remain unclear. The antitumor antibiotic mithramycin prolongs survival of mouse models of Huntington's disease in vivo and inhibits oxidative stress-induced death in cortical neurons in vitro. We had correlated protection by mithramycin with its ability to bind to GC-rich DNA and globally...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21543616
DOI: 10.1523/jneurosci.0710-11.2011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mithramycin Is a Gene-Selective Sp1 Inhibitor That Identifies a Biological Intersection between Cancer and NeurodegenerationPMID 21543616Read ↗

A Novel Transcriptional Inhibitor Induces Apoptosis in Tumor Cells and Exhibits Antiangiogenic ActivitySemantic proximity Read ↗

Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.Semantic proximity Read ↗

Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic AgentsSemantic proximity Read ↗

ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell linesSemantic proximity Read ↗

Case-specific potentiation of glioblastoma drugs by pterostilbene.Semantic proximity Read ↗

A cell type-selective apoptosis-inducing small molecule for the treatment of brain cancerSemantic proximity Read ↗

PRMT1 promotes neuroblastoma cell survival through ATF5Semantic proximity Read ↗

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant gliomaSemantic proximity Read ↗

Cytotoxic effects of auraptene against a human malignant glioblastoma cell line.Semantic proximity Read ↗

BindingDB Entry 2025: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.Semantic proximity Read ↗

Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells.Semantic proximity Read ↗

Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53-mediated apoptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.